Pub Date : 2019-08-01DOI: 10.1007/S11888-019-00440-4
G. Georgakis, Iliya Goldberg, A. Sasson
{"title":"Current Trends in the Surgical Management of Colorectal Cancer Liver Metastases","authors":"G. Georgakis, Iliya Goldberg, A. Sasson","doi":"10.1007/S11888-019-00440-4","DOIUrl":"https://doi.org/10.1007/S11888-019-00440-4","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/S11888-019-00440-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47187198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-01DOI: 10.1007/S11888-019-00436-0
A. Griffith, H. Sanoff
{"title":"Current Trends in Systemic Therapies in Elderly Patients With Metastatic Colorectal Cancer","authors":"A. Griffith, H. Sanoff","doi":"10.1007/S11888-019-00436-0","DOIUrl":"https://doi.org/10.1007/S11888-019-00436-0","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/S11888-019-00436-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42770993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-01DOI: 10.1007/s11888-019-00438-y
M. Greally, D. Ilson
{"title":"Duration of Adjuvant Chemotherapy in Colon Cancer: Current Standards and New Updates","authors":"M. Greally, D. Ilson","doi":"10.1007/s11888-019-00438-y","DOIUrl":"https://doi.org/10.1007/s11888-019-00438-y","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00438-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42377141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-10DOI: 10.1007/S11888-019-00437-Z
S. Kamatham, F. Shahjehan, P. Kasi
{"title":"Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions","authors":"S. Kamatham, F. Shahjehan, P. Kasi","doi":"10.1007/S11888-019-00437-Z","DOIUrl":"https://doi.org/10.1007/S11888-019-00437-Z","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/S11888-019-00437-Z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43463646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-17DOI: 10.1007/s11888-019-00439-x
L. Triest, C. Debeuckelaere, T. Vandamme, B. Heuvel, J. Brande, K. Papadimitriou, M. Rasschaert, H. Prenen, M. Peeters
{"title":"Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?","authors":"L. Triest, C. Debeuckelaere, T. Vandamme, B. Heuvel, J. Brande, K. Papadimitriou, M. Rasschaert, H. Prenen, M. Peeters","doi":"10.1007/s11888-019-00439-x","DOIUrl":"https://doi.org/10.1007/s11888-019-00439-x","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00439-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49543649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-15DOI: 10.1007/s11888-019-00433-3
M. Teke, Valerie-Sue Emuakhagbon
{"title":"Trends in Colorectal Cancer Surveillance: Current Strategies and Future Innovations-","authors":"M. Teke, Valerie-Sue Emuakhagbon","doi":"10.1007/s11888-019-00433-3","DOIUrl":"https://doi.org/10.1007/s11888-019-00433-3","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00433-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43603765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.1007/s11888-019-00434-2
M. Chevallay, Jérémy Meyer, Charles-Henri Wassmer, F. Ris, C. Toso, N. Buchs
{"title":"Current Trends in the Management of Low Rectal Tumors: Transanal Total Mesorectal Excision","authors":"M. Chevallay, Jérémy Meyer, Charles-Henri Wassmer, F. Ris, C. Toso, N. Buchs","doi":"10.1007/s11888-019-00434-2","DOIUrl":"https://doi.org/10.1007/s11888-019-00434-2","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00434-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41931132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01Epub Date: 2019-03-20DOI: 10.1007/s11888-019-00430-6
Rebecca A DeStefanis, Jeremy D Kratz, Philip B Emmerich, Dustin A Deming
Purpose of review: Treatment options for patients with metastatic colorectal cancer continue to advance as the therapeutic implications of the molecular subtypes of this disease are becoming better understood. DNA sequencing and mismatch repair assessment are now standard of care analyses for patients with metastatic colorectal cancer Thi review describes important aspects of the biology of the clinically relevant molecular subtypes of colorectal cancer based on the current standard of care testing. In addition, the clinical treatment strategies available now and potentially in the future for these colorectal cancer subtypes are discussed.
Recent findings: Currently for metastatic colorectal cancer, standard of care molecular testing is done for mutations in exons 2, 3, and 4 of KRAS and NRAS, and BRAF V600E. Testing for mismatch repair (MMR) deficiency/microsatellite instability (MSI) status is also done. These aberrations are well known to change the clinical prognosis and guide patients' treatment strategies. Additionally, three new subtypes have emerged: PIK3CAmut, HER2 amplified, and NTRK fusions. With the addition of these emerging subtypes, tumor heterogeneity further validates the need to examine mCRC as a heterogeneous disease. Here we present recent exciting data from translational research and clinical trials exhibiting possible distinct treatment strategies for these different subtypes.
Summary: Altogether these data show promising treatment strategies for many of these well-known and emerging subtypes of mCRC. In addition, these also give better clinical prognostic and predictive information. We believe that as molecular testing expands PIK3CA mutation, HER2 amplification, and NTRK fusion molecular testing will be included in standard of care analyses. This incorporation of testing in clinical practice will generate further information regarding prognostic and therapeutic options for these and other CRC subtypes in the future.
{"title":"Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.","authors":"Rebecca A DeStefanis, Jeremy D Kratz, Philip B Emmerich, Dustin A Deming","doi":"10.1007/s11888-019-00430-6","DOIUrl":"10.1007/s11888-019-00430-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Treatment options for patients with metastatic colorectal cancer continue to advance as the therapeutic implications of the molecular subtypes of this disease are becoming better understood. DNA sequencing and mismatch repair assessment are now standard of care analyses for patients with metastatic colorectal cancer Thi review describes important aspects of the biology of the clinically relevant molecular subtypes of colorectal cancer based on the current standard of care testing. In addition, the clinical treatment strategies available now and potentially in the future for these colorectal cancer subtypes are discussed.</p><p><strong>Recent findings: </strong>Currently for metastatic colorectal cancer, standard of care molecular testing is done for mutations in exons 2, 3, and 4 of <i>KRAS</i> and <i>NRAS</i>, and <i>BRAF</i> V600E. Testing for mismatch repair (MMR) deficiency/microsatellite instability (MSI) status is also done. These aberrations are well known to change the clinical prognosis and guide patients' treatment strategies. Additionally, three new subtypes have emerged: <i>PIK3CAmut</i>, <i>HER2</i> amplified, and <i>NTRK</i> fusions. With the addition of these emerging subtypes, tumor heterogeneity further validates the need to examine mCRC as a heterogeneous disease. Here we present recent exciting data from translational research and clinical trials exhibiting possible distinct treatment strategies for these different subtypes.</p><p><strong>Summary: </strong>Altogether these data show promising treatment strategies for many of these well-known and emerging subtypes of mCRC. In addition, these also give better clinical prognostic and predictive information. We believe that as molecular testing expands <i>PIK3CA</i> mutation<i>, HER2</i> amplification, and <i>NTRK</i> fusion molecular testing will be included in standard of care analyses. This incorporation of testing in clinical practice will generate further information regarding prognostic and therapeutic options for these and other CRC subtypes in the future.</p>","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00430-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36999935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01DOI: 10.1007/s11888-019-00432-4
Divya B. Bhatt, Valerie-Sue Emuakhagbon
{"title":"Current Trends in Colorectal Cancer Screening","authors":"Divya B. Bhatt, Valerie-Sue Emuakhagbon","doi":"10.1007/s11888-019-00432-4","DOIUrl":"https://doi.org/10.1007/s11888-019-00432-4","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00432-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43426459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-12DOI: 10.1007/s11888-019-00435-1
A. Saeed, Fariha Eshrat, S. Umar, A. Saeed
{"title":"The Duplex Interaction of Microbiome with Chemoradiation and Immunotherapy: Potential Implications for Colorectal Cancer","authors":"A. Saeed, Fariha Eshrat, S. Umar, A. Saeed","doi":"10.1007/s11888-019-00435-1","DOIUrl":"https://doi.org/10.1007/s11888-019-00435-1","url":null,"abstract":"","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-019-00435-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42072783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号